Hepatitis Treatment Hepatitis C Treatment and Sustained Virologic Response By Charles Daniel Charles Daniel Charles Daniel, MPH, CHES is an infectious disease epidemiologist, specializing in hepatitis. Learn about our editorial process Updated on March 17, 2021 Medically reviewed by Anju Goel, MD, MPH Medically reviewed by Anju Goel, MD, MPH LinkedIn Anju Goel, MD, MPH, is a board-certified physician who specializes in public health, communicable disease, diabetes, and health policy. Learn about our Medical Expert Board Print A sustained virologic response (SVR) for people with a hepatitis C infection simply means that no hepatitis C virus (HCV) can be found in blood at 12 and 24 weeks after completing a course of hepatitis C treatment. SVR very likely means that the HCV infection is cured, and has been used in studies as the ultimate goal of HCV therapy. In most cases, if HCV viral load remains undetectable 24 weeks after the completion of treatment, it remains undetectable for life. In almost all cases, people with an SVR of 24 weeks are unlikely to experience viral rebound (i.e., a return of virus). Paul Bradbury / Getty Images Defining SVR and Other Virologic Responses Following the initiation of hepatitis C therapy, the blood is tested to measure the quantity of the hepatitis C virus (the viral load). The ultimate goal is to achieve an undetectable viral load. "Undetectable," in this case, doesn't necessarily mean zero or the complete absence of viral activity in the body; rather, it is defined as having no detectable virus in the blood using current testing technologies. Each stage of response is given a classification, with some stages correlating to a greater or lesser likelihood of treatment success. Take a look at this chart, below. Term Meaning Definition Prognosis RVR Rapid viral response An undetectable viral load after four weeks of treatment Generally more likely to achieve SVR eRVR Extended rapid viral response An undetectable viral load at week 12, following the initial RVR Generally more likely to achieve SVR EVR Early viral response An undetectable viral load or a 99 percent reduction in viral load by week 12 Failure to achieve EVR correlates to less than a 4 percent chance of achieving SVR ETR End of treatment response An undetectable viral load achieved by the end of week 12 Not helpful in predicting treatment outcomes Partial responder Able to achieve EVR but unable to sustain an undetectable viral load 24 weeks after therapy completion Considered treatment failure Null responder Unable to achieve EVR by week 12 Treatment is typically terminated if EVR is not achieved by week 12 SVR Sustained viral response Able to sustain an undetectable viral load for 12 weeks (SVR-12) and 24 weeks (SVR-24) following completion of therapy SVR-24 is considered a “cure,” and patients with SVR-12 are usually able to achieve SVR-24 Increasing Your Chances of Achieving SVR One of the main determinants of SVR success is timing. Treatment, when you have been infected for a short time, is somewhat more likely to work than treatment in patients who have been infected for many years. By treating your infection before there is marked liver damage, you generally have a better chance of achieving a clinical cure for HCV. Additionally, newer-class direct-acting antivirals (DAAs) have had a profound effect on SVR rates in people with chronic HCV infection. Even in people with compensated cirrhosis, who had previously had a 50/50 chance of treatment success, SVR rates have gradually climbed to 95 percent and above in many of these cases. What Failing to Achieve SVR Means While the goal of HCV therapy is to effectively eradicate the virus and to allow a person to live a healthy, hepatitis-free life, a patient shouldn't despair if he or she is unable to achieve these goals. Even if you have only a partial response, studies have shown that the benefits to the liver can be profound—not only slowing the course of the disease but in some cases reversing fibrosis, even in those with marked liver damage. If you fail your first or second round of therapy, take time to monitor your blood results with your healthcare provider. If you feel that you are ready to try again, your healthcare provider can perform a number of tests to determine which drugs may provide you with the best chance of achieving SVR success. Reasons Why You May Not Achieve SVR It's not entirely clear why a small percentage of patients don't reach SVR, but the following factors can play a role: Failure to adhere to treatment or complete treatment The specific genotype of your hepatitis Underlying liver diseaseA drug-resistant virusConcurrent HIVBaseline viral loadAlcohol useAge Coping With Hepatitis C Don't let a hepatitis C infection make you feel isolated. There is help available. Beyond asking your friends and family members to help you during your journey, you may find comfort joining the active hepatitis C community online or a chronic hepatitis support group. Also, learning more about chronic hepatitis nutrition can both make you feel better and potentially improve your treatment response. 4 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. US Department of Veterans Affairs. FAQs about Sustained Virologic Response to Treatment for Hepatitis C. October 2015. Naggie S. Management of hepatitis C virus infection: the basics. Top Antivir Med. 2012;20(5):154-61. UpToDate. Direct-acting Antivirals for the Treatment of Hepatitis C Virus Infection. National Health Service. Hepatitis C. Additional Reading Kattakuzhy, S., Wilson, E., Sidharthan, S. et al. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clinical Infectious Disease. 2016. 62(4):440-7. doi:10.1093/cid/civ897 Smith-Palmer, J., Cerri, K., and W. Valentine. Achieving Sustained Virologic Response in Hepatitis C: A Systematic Review of the Clinical, Economic and Quality of Life Benefits. BMC Infectious Disease. 2015. 15:19. doi:10.1186/s12879-015-0748-8 Chopra, S., and D. Muir. Treatment Regimens for Chronic Hepatitis C Virus Genotype 1. UpToDate. Updated 09/14/16. Kattakuzhy, S., Wilson, E., Sidarthan, S. et al. Evolution of Resistance Associated Variants During Initial Treatment, Viral Failure, and Re-Treatment with Directly Acting Antiviral Therapy (NIH SYNERGY Trial). AASLD Liver Meeting; 2015; abstract 220. By Charles Daniel Charles Daniel, MPH, CHES is an infectious disease epidemiologist, specializing in hepatitis. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Accept All Cookies